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The oral delivery of docetaxel (DTX) is challenging due to a low bioavailability, related to 
an important pre-systemic metabolism. With the aim of improving the bioavailability of 
this cytotoxic agent, nanoparticles from conjugates based on the copolymer of methyl 
vinyl ether and maleic anhydride (poly(anhydride)) and two different types of PEG, 
PEG2000 (PEG2) or methoxyPEG2000 (mPEG2), were evaluated. Nanoparticles, with a 40 
DTX loading close to 10%, were prepared by desolvation and stabilized with calcium, 
before purification and lyophilization. For the pharmacokinetic study, nanoparticles 
were orally administered to mice at a single dose of 30 mg/kg. The plasma levels of DTX 
were high, prolonged in time and, importantly, quantified within the therapeutic 
window. The relative oral bioavailability was calculated to be up to 56% when DTX was 45 
loaded in nanoparticles from poly(anhydride)-mPEG2000 conjugate (DTX-NP-mPEG2). 
Finally, a comparative toxicity study between equitoxic doses of free iv DTX and oral 
DTX-NP-mPEG2 was conducted in mice. Animals orally treated with DTX-loaded 
nanoparticles displayed less severe signs of hypersensitivity reactions, peripheral 
neurotoxicity, myelosuppression and hepatotoxicity than free iv docetaxel. In summary, 50 
poly(anhydride)-PEG conjugate nanoparticles appears to be adequate carries for the 
oral delivery of docetaxel. 
 
 











Docetaxel (DTX), is an antineoplasic agent belonging to the second generation of the 65 
taxoid family. This semisynthetic analogue of paclitaxel displays a broad spectrum of 
antitumor activity and it is considered one of the most potent anticancer drugs in the 
clinical setting (Verweij et al., 1994; Zhang et al., 2019). It was first described in the 1980s 
but it was not until the mid 1990s that it was approved by the FDA and consequently 
used in clinical practice. Docetaxel is a cytotoxic agent that promotes tubulin assembly, 70 
stabilizes microtubules and inhibits their depolymerisation, thereby causing mitotic 
arrest in the G2/M phase of the cell cycle and, subsequently, inducing apoptosis (Ogura 
et al., 2016). Clinically it is widely employed for the treatment of breast, prostate, head 
and neck, gastric, and non-small cell lung cancers (de Weger et al., 2014). 
However, the clinical application of docetaxel is limited by the poor aqueous solubility 75 
(4.93 μg/ml), high toxicity and low bioavailability (Dou et al., 2015). The available 
commercial formulation, Taxotere® or its generic forms, includes a high concentration 
of Tween® 80 and ethanol (50:50 v/v) as excipients for its intravenous administration 
(Haiqun et al., 2014). Serious dose-limiting toxicities and unpredictable adverse 
reactions due to either the drug itself or the solvent system have been reported in 80 
patients, such as hypersensitivity reactions (Pellegrino et al., 2017), myelosuppression 
(specially neutropenia) (Hennenfert and Govindan, 2006) and neurotoxicity (Fredriks et 
al., 2015), requiring the oral administration of corticosteroids and antihistamines before 
infusion (Mazzaferro et al., 2012). On the other hand, the oral administration of 
docetaxel is hampered by both its high lipophilicity and low mucosal permeability. In 85 
fact, docetaxel is considered as a class IV compound within the Biopharmaceutical 
classification system (BCS). The permeability of this anticancer drug is hampered by its 
high affinity for the multidrug efflux transporter P-glycoprotein (P-gp) and the 
cythocrome P450 enzymatic complex. Both, transporter and metabolic enzymes, are 
highly expressed in the gastrointestinal (GI) tract limiting the permeation of the drug 90 
through the intestinal membrane (van Herwaarden et al., 2007; van Waterschoot et al., 
2009). 
In order to overcome these drawbacks and improve the oral absorption (bioavailability) 
of docetaxel, a number of different strategies have been proposed. Among others, the 
following attempts can be highlighted: coadministration with P-gp selective inhibitors 95 
(Malingré et al., 2001; Patel et al., 2015), synthesis of docetaxel analogues (i.e. 
cabazitaxel, larotaxel) (Vrignaud et al., 2013; Muggia and Kudlowitz, 2014) and the use 
of formulation approaches such as the combination with cyclodextrins (Wun et al., 2013) 
or the incorporation in solid dispersions (Song et al., 2016), microemulsions (Yin et al., 
2009), nanoemulsions (Pandey et al, 2017), self-nanoemulsifying drug delivery systems 100 
(SNEDDS) (Seo et al., 2013), micelles (Hekmat et al., 2016), and nanoparticles (Cho et al., 
2014; Feng et al., 2019). 
In this context one interesting approach may be the use of nanoparticles from 
conjugates based on the copolymer of methyl vinyl ether and maleic anhydride 
(Gantrez® AN). These nanoparticles have been proposed in the recent past as carriers 105 
for the mucosal delivery of drugs (Arbós et al., 2003; Yoncheva et al., 2005a). This 
copolymer is extremely reactive, offering the possibility to react with a large variety of 
nucleophile and functional groups such as alcohols and amines. In this work, we have 
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selected the combination between Gantrez® AN and poly(ethylene glycol) to produce 
pegylated nanoparticles. In fact, the coating of these poly(anhydride) nanoparticles with 110 
PEGs would result in mucus-permeating carriers capable of reaching the surface of the 
mucosal epithelium in which they would release the loaded drug (Zabaleta et al., 2013; 
Inchaurraga et al., 2015). In addition, PEGs have been identified as inhibitors of the 
intestinal P-gp efflux pump (Hugger et al., 2002). Last but not least, the oral toxicity of 
poly(anhydride) nanoparticles combined with PEGs has been evaluated in vivo 115 
confirming its oral safety (Yoncheva et al., 2005b). Particularly, the investigations 
demonstrated that LD50 was higher than 2000 mg/kg body weight. 
Therefore, in this study, the potential use of nanoparticles prepared from Gantrez® AN-
PEG conjugates as carriers for the oral delivery of docetaxel was investigated. In a first 
step, the Gantrez® AN-poly(ethylene glycol) conjugates were synthesised and 120 
characterized. In a second step, these conjugates were used to prepare DTX-loaded 
nanoparticles. Finally, the pharmacokinetic profiles and the toxicity of DTX-loaded 
nanoparticles were evaluated in Balb/c mice. 
 
 125 
2. Material and methods 
2.1 Materials 
Poly(methyl vinyl ether-co-maleic anhydride) or poly(anhydride) (PMV/MA) [Gantrez® 
AN 119; MW 200,000] was purchased from International Specialty Products ISP/Ahsland 
Inc (KY, USA). Docetaxel (USP 30, grade 99.0%) and paclitaxel (USP 28, grade >99.5%) 130 
were supplied by 21CECpharm (London, UK). Taxotere®, from Sanofi-Aventis, was 
provided by the Pharmacy Service of University Clinic of Navarra (Pamplona, Spain). 
Phosphate buffered saline (PBS), pancreatin, methoxy poly(ethylene glycol) 2000 
(mPEG2000) and solid iodine (≥99.8%) were obtained from Sigma Aldrich (MO, USA). 
Poly(ethylene glycol) with MW of 2000 Da (PEG2000) was provided by Fluka (Buchs, 135 
Switzerland). Acetone, ethanol, t-buthylmethylether, acetonitrile and tetrahydrofuran 
(THF) were obtained from Merck (Darmstadt, Germany). Polysorbate 80 (Tween® 80) 
was supplied by Panreac (Barcelona, Spain). Deionised reagent water (18.2 MΩ 
resistivity) was prepared by a water purification system (Wasserlab, Pamplona, Spain). 
The anaesthetic isoflurane (Isoflo®) was from laboratories Esteve (Barcelona, Spain). All 140 
other reagents and chemicals used were of analytical grade and supplied from Sigma 
Aldrich (MO, USA) and Merck (Darmstadt, Germany). 
 
2.2 Preparation of Gantrez® AN-poly(ethylene glycol) conjugates (PEG2 and mPEG2) 
Two sets of Gantrez® AN based-conjugates with either poly(ethylene glycol) 2000  or 145 
methoxy poly(ethylene glycol) 2000 were synthetized. 
For the preparation of Gantrez-PEG2000 conjugate (PEG2), 500 mg Gantrez® AN were 
firstly dissolved in 100 mL acetone and heated at 50ºC. Then, 25 mg PEG2000 was 
dissolved in 25 mL acetone and added to the polymer solution by dripping. The mixture, 
heated at 50ºC, was stirred under magnetic stirring for 3 h. Then, the solvent was 150 
eliminated by reduced pressure evaporation and the residue was dried (Büchi 
Rotavapor® R-144; Büchi, Postfach, Switzerland). After collecting the solid, the powder 
was dispersed in 25 mL dicloromethane in order to eliminate the remaining free 
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PEG2000. The mixtures were sonicated for 1 min and the supernatant was harvested 
under vacuum (all-glass filter, Merck Millipore, Darmstadt, Germany). The supernatants 155 
were analyzed by TLC (mobile phase dicloromethane-methanol 9:1 v:v) and developed 
with solid iodine in order to determine the presence of free PEG. The washing process 
of conjugates with dicloromethane was repeated until the TLC of the supernatant did 
not show any presence of PEG. 
The conjugate between mPEG2000 and Gantrez® AN (mPEG2) was prepared and 160 
purified in the same way as described before with the only difference that the ratio 
between mPEG2000 and Gantrez® AN was 0.20 (100 mg mPEG and 500 mg polymer). 
 
2.3 Physico-chemical characterization of Gantrez® AN-poly(ethylene glycol) 
conjugates 165 
After the synthesis, the resulting Gantrez® AN based-conjugates were characterized in 
order to confirm the binding of the ligand (PEG2000 or mPEG2000) to the polymer 
backbone as well as to estimate the molecular weight (MW) and the degree of 
substitution of the resulting compounds.  
2.3.1 Infrared spectroscopy (IR) 170 
IR spectroscopy was carried out in a Nicolet Avatar 360FT-IR apparatus (Thermo, WI, 
USA). This technique allowed us to identify the presence of the carbonyl groups v (C=O) 
in order to put in evidence the opening of the anhydride ring in the Gantrez® AN 
backbone through a chemical interaction and the formation of a bond between the 
carbonyl group of the polymer and a hydroxyl group of the poly(ethylene glycol) 175 
(PEG2000 or mPEG2000). 
2.3.2 Nuclear magnetic resonance spectroscopy (1H-NMR) 
1H-NMR studies were performed in an Avance 400 apparatus (Bruker, WI, USA) of 400 
MHz, using a pulse program zg30 and a waiting time pulses (D0) of 1 s. The number of 
accumulations was 64. Thus, exactly weighted amounts of the Gantrez conjugates (2 180 
mg) were dissolved in 500 μL deuterated acetone. 
The amounts of PEGs associated to the nanoparticles were calculated as described 
previously (Ojer et al., 2012). For this purpose, the integration of the signal 
corresponding to the methylated proton in the Gantrez® AN (δHa at 4.25 ppm) was used 
as reference. For PEG2000 and mPEG2000, the reference signals were bands produced 185 
by protons identified with δHe at 3.59 ppm and δHf at 3.62 ppm, respectively (see 
supplementary material). The amount of the PEG (PEG2000 or mPEG2000) bound to the 
polymer backbone in the synthetised conjugates was then estimated using the following 
δHa/ δHe and δHa/ δHf ratios. 
2.3.3 HPLC with Evaporative Light Scattering Detector (HPLC-ELSD) 190 
The amounts of PEG bound to the polymer were also estimated by HPLC (Agilent model 
1100 series LC, Agilent, Wokingham, UK) coupled to an Evaporative Light Scattering 
Detector (ELSD) (Alltech, NY, USA) following the procedure reported by Zabaleta et al. 
with minor modifications (Zabaleta et al., 2007). Separation was carried out on a PL-
aquagel-OH column (300 mm x 7.5 mm; particle size 5 μm) (Agilent, Wokingham, UK), 195 
in a gradient elution with methanol-water as mobile phase at a flow rate of 1mL/min. 
ELSD conditions were optimized in order to achieve maximum sensitivity: the drift tube 
temperature was set at 90ºC, the nitrogen flow was maintained at 3.2 L/min and the 
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gain was set to 2. Under these experimental conditions, retention times for PEG2000 
and mPEG2000 were 7.1 ± 0.03 and 6.9 ± 0.08 min, respectively.  200 
For calculations, an exactly weighed amount of non-purified conjugate was dissolved in 
5 mL acetone. Then, 5 mL of ethanol followed by 5 mL of an aqueous solution containing 
2% (v/v) CaCl2 0.8% were added and the just formed suspension was centrifuged at 
27,000xg for 20 min (Sigma 3 K30, Munich, Germany). The supernatants were collected 
and quantified by HPLC as described above. The amount of either PEG2000 or 205 
mPEG2000 bound to the poly(anhydride) backbone was calculated as the difference 
between the initial PEG added for the preparation of the conjugates and the amount of 
PEG recovered from the supernatants. Each sample was assayed in triplicate and the 
results were expressed as the amount of poly(ethylene glycol) per mg of conjugate. 
 210 
2.4.   Preparation of DTX-loaded nanoparticles (DTX-NP-PEG2 and DTX-NP-mPEG2) 
Briefly, 100 mg conjugate (PEG2 or mPEG2) were dissolved in 3 mL acetone. In parallel, 
10 mg DTX were dispersed in 2 mL acetone. Both phases (conjugate and docetaxel) were 
then mixed under magnetic stirring and the nanoparticles formed by the addition of 5 
mL of ethanol followed by the addition of 5 mL of an aqueous solution containing 2% 215 
(v/v) CaCl2 0.8%. The organic solvents were eliminated by evaporation under reduced 
pressure and the resulting suspensions were filtered through a 0.45 m membrane and 
purified by centrifugation (Sigma 3 K30, Munich, Germany) at 27,000xg for 20 minutes. 
The pellets were resuspended in water and the purification step was repeated again. 
Finally, the formulations were frozen and freeze-dried (Genesis 12EL Freeze Dryer; 220 
Virtis, PA, USA) using sucrose (5% w/v) as cryoprotector.  
Empty nanoparticles (NP-PEG2 and NP-mPEG2) were prepared in the same way as 
described above but in absence of docetaxel and used as controls. 
For the identification of the different pegylated nanoparticle formulations, the following 
abbreviations were used: NP-PEG2 (nanoparticles prepared from the conjugate 225 
between Gantrez®AN and PEG2000), NP-mPEG2 (nanoparticles prepared from the 
conjugate between Gantrez®AN and mPEG2000), DTX-NP-PEG2 (docetaxel-loaded 
nanoparticles prepared from the conjugate between Gantrez®AN and PEG2000) and 
DTX-NP-mPEG2 (docetaxel-loaded nanoparticles prepared from the conjugate between 
Gantrez®AN and mPEG2000). 230 
 
2.5 Characterization of DTX-loaded nanoparticles 
2.5.1 Physico-chemical characterization 
The size and zeta potential of the systems were determined by photon correlation 
spectroscopy (PCS) and electrophoretic laser Doppler anemometry, respectively, using 235 
a Zetaplus analyser system (Brookhaven Instruments Corporation, NY, USA). The 
nanoparticles mean diameter was determined after dispersion in ultrapure water and 
measured at 25ºC by dinamic light scattering angle of 90ºC, and the surface charge was 
determined by dilution of 200 μL the samples in 2 mL of a 0.1 mM KCl solution (pH 7.4). 
The yield of the process was calculated by gravimetry as described previously (Arbós et 240 
al., 2003).  
The morphology and shape of the nanoparticles were examined and 
microphotographed by field emission scanning electron microscopy (FESEM) in a Zeiss 
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Ultra Plus scanning electron microscope (Carl Zeiss SMT, Oberdochen, Germany) 
operating between 1 and 2 kV from 3 mm distance. Prior analysis and in order to 245 
enhance the quality of the images, particles were washed to remove the cryoprotector. 
For this purpose, freeze-dried nanoparticles were resuspended in ultrapure water and 
centrifuged at 27,000xg for 10 min. Then, the supernatants were rejected and the 
obtained pellets were mounted on copper grids. Finally, the pellet was shaded with a 
gold/palladium (Au/Pd) layer in a Q150R Sputter-Coater (Quorum Technologies, 250 
Ashford, UK). 
2.5.2 Docetaxel content in nanoparticles 
The amount of docetaxel loaded into nanoparticles was quantified by HPLC-UV in an 
Agilent model 1200 series LC coupled to a diode-array detector (Agilent) set at 228 nm. 
The chromatographic system was equipped with a reversed-phase 150 mm x 3 mm C18 255 
Phenomenex Gemini column (particle size 5 μm; Phenomenex, CA, USA) and protected 
by a 0.5 μm precolumn filter. The mobile phase consisted of phosphate buffer (0.01 M; 
pH 2.1) and acetonitrile (50:50 v/v) eluted at 0.5 mL/min. The column was placed at 30°C 
and the injection volume was 100 μL. Paclitaxel (PTX) was used as internal standard. 
Under these experimental conditions the run time was 16 min and paclitaxel and 260 
docetaxel eluted at 6.8 and 8.2 min, respectively. For the calculations, the standard 
curve of docetaxel was designed over the range between 1.25 and 320 μg/mL (r20.999). 
The limit of quantification was calculated as 60 ng/mL with a relative standard deviation 
of 4.5 %. For analysis, nanoparticles were digested with acetonitrile (1:8 volume ratio) 
and assayed in triplicate. The results were expressed as the amount of DTX (μg) per mg 265 
of nanoparticles. The encapsulation efficiency (E.E) was calculated as follows:  
 E.E (%) = (Qassociated/Qinitial) x 100    (Eq.1) 
Where Qinitial is the initial amount of DTX added and Qassociated is the amount of entrapped 
DTX in the nanoparticles which is calculated by HPLC. 
 270 
2.6 In vitro release study  
In vitro drug release experiment was carried out at 37°C using simulated gastric (SGF; 
pH 1.2) and intestinal (SIF; pH 6.8) fluids containing 0.5% of polysorbate 80 (Tween® 80) 
as solubilising agent for docetaxel to maintain sink conditions.  
Drug-release patterns were evaluated by using dialysis cassettes (Slide-A-Lyzer®, 275 
Thermo Scientific, MA, USA; MW cut off: 10,000). For this purpose, dialysis cassettes 
were filled with a suspension of nanoparticles in water (containing 7.5 mg docetaxel) 
and placed in 300 mL of SGF at 37ºC under magnetic stirring for two hours. As control, 
free docetaxel (dissolved in distilled water containing 25% Tween 80 and 9.75% ethanol) 
was employed. After 2 h under SGF, the cassettes were collected and placed in 300 mL 280 
SIF at the same temperature. At predetermined time intervals, 1 mL samples were 
withdrawn from the receptor compartment and replaced immediately with the same 
volume of fresh simulated fluid to maintain a constant release volume. Finally, samples 
were filtered and the amount of docetaxel released from the formulations was 
quantified by HPLC analysis as previously described (calibration curves of free docetaxel 285 
in supernatants obtained from SGF and SIF, r20.999). Release profiles were expressed 




2.7 Pharmacokinetic studies  
Pharmacokinetic studies were performed on Balb/c female mice (average weight 19-22 290 
g) obtained from Harlan (Santiga, Spain). Animal experiments were carefully reviewed 
and approved by the Ethical Committee for Animal Experimentation at the University of 
Navarra (Spain) (protocol number 169-12). Before the experiment, animals were 
adaptively fed for 1 week with free access to food and drinking water (12 h day/night 
cycle, temperature 22 ± 2°C, relative humidity 55 ± 10%). The mice were fasted 295 
overnight prior to the study.  
The animals were randomly divided into treatment groups (n=16). Each time point 
corresponded to 4 animals. The experimental groups were as follows: (a) DTX-NP-PEG2 
and (b) DTX-NP-mPEG2. Nanoparticles were dispersed in purified water and each animal 
received orally a volume (about 200 μL) of nanoparticle suspension, corresponding to a 300 
docetaxel dose of 30 mg drug per kg body weight (bw), with a blunt needle via the 
esophagus into the stomach. As controls, one group of animals received Taxotere® (DTX) 
intravenously via the tail vein as a slow infusion and another group was treated with the 
commercial formulation orally. In both cases, the anticancer drug was diluted with 
either purified water (oral) or sterile saline (intravenous) and the dose was again 30 305 
mg/kg body weight. All the animals were observed for their general condition and 
clinical signs.  
Blood samples were obtained from four animals per time point at 0, 0.08, 0.25, 0.5, 1, 
2, 4, 6, 8 and 12 h following iv administration and 0, 0.5, 1, 1.5, 3, 4, 6, 8, 12, 24, 48 and 
72 h following oral administration. EDTA was used as an anticoagulant agent. Blood 310 
volume was recovered intraperitoneally with an equal volume of normal saline solution 
preheated at body temperature. The plasma was separated into clean tubes by 
centrifugation at 2,500xg for 10 minutes and kept frozen at -80ºC until HPLC analysis. 
2.7.1 Determination of DTX plasma concentration by HPLC-UV 
The amount of docetaxel was determined in plasma by HPLC-UV as described above. 315 
The extraction method was adapted from Zhao et al. (2009). Calibration curves were 
used for the conversion of the DTX/PTX chromatographic area to the concentration. 
Calibrator and quality control samples were prepared by adding appropriate volumes of 
standard docetaxel ethanolic solution to drug free plasma. Calibration curves were 
designed over the range between 100 and 3200 ng/mL (r2>0.999). An aliquot (200 μL) 320 
of plasma was mixed with 25 μL of internal standard solution (paclitaxel, 10 μg/mL in 
ethanol). After vortex mixing, liquid–liquid extraction was accomplished by adding 3 mL 
of tert-buthylmethylether following vortex gentle agitation (10 min). The mixture was 
centrifuged for 10 min at 2,500xg, and then, the organic layer was transferred to a clean 
tube and evaporated until dry (Thermo Savant, Barcelona, Spain). Finally, the residue 325 
was dissolved in 125 μL of reconstitution solution (acetonitrile–phosphate buffer; 0.01 
M; pH=2.1; 50:50 v/v) and placed in the HPLC. A hundred microlitre-aliquot of each 
sample was injected onto the HPLC column. Under these experimental conditions, the 
UV detection of docetaxel was performed at 228 nm and the run time was 16 min. The 
limit of quantification was calculated to be 140 ng/mL with a relative standard deviation 330 
of 5.3%.  
2.7.2 Calculation of pharmacokinetic parameters 
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The pharmacokinetic analysis was performed based on a non-compartmental model 
using WinNonlin 5.2 software (Pharsight Corporation, MO, USA). The following 
parameters were estimated: maximal plasmatic concentration (Cmax), time in which the 335 
maximum concentration is reached (Tmax), area under the concentration-time curve 
from time 0 to t h (AUC), mean residence time (MRT), clearance (Cl), volume of 
distribution (V) and half-life of the terminal phase (t1/2z). Furthermore, the relative oral 
bioavailability (Fr) of docetaxel was calculated using the ratio of dose-normalized AUC 
values following oral and iv administrations:  340 
 Fr (%)=AUCoral/ AUCiv x 100  (Eq.2) 
Where AUCoral and AUCiv.  correspond to the areas under the plasmatic curve for the oral 
and intravenous administrations, respectively. 
 
2.8 In vivo toxicity studies 345 
Toxicity studies were performed on Balb/c female mice (average weight 19-22 g) 
purchased from Harlan (Santiga, Spain). Animal experiments were carried out in 
compliance with the regulations of the responsible committee of the University of 
Navarra (Spain) (protocol number 169-12) in line with the European legislation on 
animal experiments (86/609/EU).   350 
On the day of arrival, animals were housed under standard facilities and given free 
access to food and drinking water. Housing conditions were maintained by control 
temperature and humidity and with 12-hour on-off light cycles. Animals were allowed 
at least 1 week to acclimate to the environment prior to any experiments. The mice were 
fasted overnight prior to the study.  355 
On the day of the experiments, mice were randomly distributed into the following 
groups: (i) Control group (non-treated animals) (n=5); (ii) DTX group (n=5) weekly 
treated with 30 mg/kg Taxotere® (after dilution in sterile saline) by the intravenous 
route via the tail vein of mice; and (iii) the nanoparticle treatment group (n=8) that 
received three times per week an oral dose of 20 mg/kg (as 200 μL of a suspension of 360 
DTX-NP-mPEG2 in water). To sum up, animals of the DTX group received three doses of 
30 mg/kg (1 dose per week), whereas the animals treated with the nanoparticle 
formulation received nine doses of 20 mg/kg (3 doses per week).  
Individual animal weights were registered on day 0 and three times per week during 35 
days. Similarly, at these time intervals defined, mice were also observed for any clinical 365 
signs of toxicity including piloerection, passivity, skin reactions, gastrointestinal toxicity 
and peripheral neuropathy. Mucosal injury, which leads to gastrointestinal toxicity such 
as vomiting and diarrhea in clinical settings, was examined. Peripheral neuropathy was 
considered as damage to the peripheral nerves with clinical observations such as 
impaired gait, hind limb foot splay, or hind limb paralysis. Reactions severity was 370 
classified in following categories depending on their severity: i) (-) absent; ii) (+) weak; 
iii) (++) moderate; and iv) (+++) strong.  
At designated times, blood samples were extracted from the retro-orbital sinus under 
isoflurane anesthesia for haematological and biochemical analysis respectively. 
Heparinized plasma used for biochemical analysis was obtained by centrifugation at 375 
2500 xg for 10 min. For hematological analysis, the following hematological parameters 
were analyzed: hemoglobin (HGB; g/L), hematocrit (HCT, %), red blood corpuscles count 
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(RBC; 106/μL), mean corpuscular volume (MCV; fl), mean corpuscular hemoglobin (MCH; 
pg), mean corpuscular hemoglobin concentration (MCHC; g/dL) and white blood 
corpuscles count (WBC; 103/μL). The blood analysis was performed on a Sysmex XT1800i 380 
hematology analyzer (Roche Diagnostics Ltd., Basel, Switzerland). WBC differential 
count was performed by microscopic examination using a Nikon Eclipse Ci microscope 
(Nikon Instruments, Melville, NY, USA). The absolute neutrophil count (ANC; 103/μL) was 
obtained using the following formula: percentage of neutrophils in the differential count 
x total WBC.  385 
For biochemical analyses, the levels of aspartate transaminase (AST; U/L), alanine 
transaminase (ALT; U/L), creatinine (mg/dL) and urea (mg/dL) were determined with a 
Hitachi 911™ autoanalyzer (Roche Diagnostics Ltd., Basel, Switzerland) using the 
protocols obtained from Roche for the determination of standard parameters. 
 390 
2.9 Statistical analysis 
Data are expressed as the mean ± S.D. of at least three experiments. The non parametric 
Kruskall-Wallis followed by U Mann-Whitney test was used to investigate statistical 
differences. In all cases, p<0.05 was considered to be statistically significant. All data 
processing was performed using GraphPad Prism 6.0 statistical software program 395 




3.1 Preparation and characterization of Gantrez® AN-poly(ethylene glycol) conjugates 400 
Figure 1 shows the infrared spectra of the poly(anhydride) and its conjugates with either 
PEG2000 or mPEG2000 (PEG2 or mPEG2 conjugates). In the analysis of the two 
derivatives, a new band at 1706 cm-1 appeared in the spectra. This band would be 
associated with the stretching of the carbonyl group v (C=O), suggesting a nucleophilic 
substitution reaction between PEG and Gantrez.  405 
Supplementary material compiles the spectra obtained from the analysis of conjugates 
from 1H-RMN. Figure 1S shows the spectrum of Gantrez® AN in which five main chemical 
shifts appear. The signal “a” corresponding to the hydrogen of the CH groups was used 
as reference for quantifications. Figures 2S and 3S display the spectra for PEG2000 and 
mPEG2000, respectively. For both PEG2000 and mPEG2000 spectra, the characteristics 410 
signals for CH2 groups were observed: 3.59 ppm (signal “e”) for PEG2000 and 3.62 ppm 
(signal “f”) for mPEG2000. All of these shifts (“a” and “e” or “f”) appeared in the spectra 
of conjugates (Figures 4S and 5S).  
From these spectra, the substitution degree (DS) and the MW of the new conjugates 
were calculated. For PEG2, the DS was calculated to be 2.1 whereas for mPEG2, this 415 
value was estimated to be 7.1. As a result, and taken into account that the MW of 
Gantrez AN (as defined by the manufacturer) was 216 kDa, the resulting conjugates 
were calculated to be 220.6 and 230.8 kDa, respectively. These results were confirmed 
by HPLC-ELSD analysis (Table 1).  
 420 
3.2 Preparation and characterization of DTX-loaded nanoparticles 
Table 2 summarizes the main physico-chemical characteristics of the different 
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docetaxel-loaded nanoparticles obtained from the Gantrez® AN-PEG conjugates. 
Nanoparticles obtained from the Gantrez® AN-PEG2000 conjugate displayed bigger sizes 
that those prepared from mPEG2. Thus, for DTX-NP-PEG2, the mean size was close to 425 
420 nm while for DTX-NP-mPEG2 the mean diameter was around 340 nm. In both cases, 
the polydispersity of nanoparticles was low with a polydispersity index (PDI) under 0.3. 
Similarly, the yield of the preparative process was quite similar and around 60%. 
Regarding zeta potential, DTX-NP-PEG2 and DTX-NP-mPEG2 formulations displayed 
negative surface charges, slightly higher for nanoparticles obtained from mPEG2 than 430 
from PEG2 conjugates (about -37 vs. 33 mV). Empty nanoparticles displayed similar 
physico-chemical characteristics than the DTX-loaded ones; except for the yield of the 
process, which was slightly higher than in the presence of the anticancer drug (about 
70%). Likewise, the mean size of empty nanoparticles was found to be slightly smaller 
than in the presence of docetaxel (see Table 2).  435 
Finally, the amount of docetaxel encapsulated into the nanoparticles was independent 
of the conjugate used to prepare these carriers.  Thus, in both cases, the drug loading 
was close to 10% (100 μg DTX/mg NP), with an encapsulation efficiency of about 60%.  
Figure 2 shows the morphology of nanoparticles when observed by FESEM. Both types 
of nanoparticles displayed a spherical shape with a slightly rough and irregular surface. 440 
Interestingly, the apparent size measured from FESEM images were found in good 
agreement with that determined by photon correlation spectroscopy. 
 
3.3 In vitro release study 
The release of docetaxel was evaluated in simulated gastric and intestinal fluids 445 
supplemented with Tween 80 (Figure 3). The dialysis membrane did not importantly 
affect the release of free docetaxel from the reservoir (Float-A-Lyzer device) to the 
external medium (SGF or SIF). When nanoparticles were dispersed in SGF for two hours, 
the amount of the loaded drug released in this period of time was always less than 10%. 
In contrast, when nanoparticles were incubated in the SIF, docetaxel was released more 450 
rapidly. For DTX-NP-PEG2, the profile was characterised by a quick initial release during 
the first 4 hours in which more than the 50% of the loaded drug was released followed 
by a more sustained deliverance phase. For DTX-NP-mPEG2, the release profile in SIF 
appeared to be linear and constant during the first 10 hours in which close to the 80% 
of the loaded drug was released. A complete release of docetaxel was obtained 455 
for all samples at 30 hours after the beginning of the study.   
 
3.4 Pharmacokinetic studies 
The plasma concentration-time curve after a single intravenous and oral administration 
of docetaxel at 30 mg/kg and the oral administration of docetaxel loaded in the different 460 
poly(anhydride)-PEG conjugate nanoparticles at 30 mg/kg are shown in Figure 4. On the 
one hand, after the iv administration of commercial docetaxel, the drug plasma 
concentration presented a nonlinear profile with detectable levels of docetaxel until 12 
hours post-administration. On the other hand, when DTX was administered orally, the 
plasma levels were below the limit of detection of the HPLC technique. By contrast, the 465 
oral administration of the poly(anhydride)-PEG conjugate nanoparticles offered high 
and sustained plasma levels of the anticancer drug. These plasma curves were 
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characterized by an initial first phase of about 1.5-2 hours in which the docetaxel plasma 
levels increased till reaching the Cmax, followed by a phase of about 70 hours in which 
the amount of the anticancer drug in plasma was found to decrease in a slow and 470 
sustained way. Moreover, it is interesting to note that docetaxel plasma levels were 
within the therapeutic window (between 35 ng/mL and 2700 ng/mL, minimum and 
maximum tolerated dose respectively) in both cases. 
Table 3 summarizes the main pharmacokinetic parameters derived from the oral and 
intravenous plasma curves estimated by a non-compartmental analysis. Firstly, for the 475 
commercial formulation administered by means if the iv route, the mean value of AUC 
was 145 μg h/ml with a maximum concentration (Cmax) of 178 μg/ml. The mean 
residence time (MRT) and the half-life of the terminal phase (t1/2z) of the curve were 
estimated to be 1.5 h. The clearance (Cl) of docetaxel was 0.2 L/h/kg and the volume of 
distribution (V) of the drug was about 0.5 L/kg. 480 
As observed in Table 3, the docetaxel Cmax for the nanoparticle formulations were found 
to be about 100-times lower than for the drug formulation administered by the iv route. 
The Tmax was delayed to 1.5 h for oral DTX-NP-mPEG2 formulation and to 2 h for oral 
DTX-NP-PEG2 formulation. Similarly, for DTX-NP-PEG2 and DTX-NP-mPEG2, AUC values 
were 2.5 and 1.8-times lower than the AUC obtained after a single intravenous 485 
administration of free docetaxel, respectively. In addition, for DTX-NP-mPEG2, AUC 
value was 1.4-fold higher than calculated for DTX-NP-PEG2. With these values, the 
relative oral bioavailability (Fr) of docetaxel was found to be 56% for DTX-NP-mPEG2 
and 40% for DTX-NP-PEG2. 
On the other hand, the mean residence time (MRT) of the drug in plasma and its half-490 
life of the terminal phase (t1/2z) were greatly extended when administered in the 
nanoparticle formulations by the oral route. Thus, the half-life of docetaxel (t1/2z) was 
about 24-29 times higher when the drug was administered orally in the nanoparticles 
than when given as free drug (DTX) by the intravenous route. In the same way, the 
volume of distribution (V) of the anticancer drug when loaded in nanoparticles was 495 
significantly higher (11.2 and 14.1 L/kg for DTX-NP-PEG2 and DTX-NP-mPEG2) than 
when the drug was intravenously administered. On the contrary, the clearance of 
docetaxel was always similar and independent of both the formulation and the route of 
administration used. 
 500 
3.5 In vivo toxicity studies 
In order to gain insight about the toxicity induced by docetaxel when administered orally 
in the form of nanoparticles, DTX-NP-mPEG2 was administered at a dose of 20 mg/kg 
three times per week during three consecutive weeks (9 doses). For comparisons, DTX 
was also administered weekly intravenously at a dose of 30 mg/kg for three consecutive 505 
weeks (3 doses). For the group of mice treated with DTX intravenously, the animals 
suffered of a significant weight loss during the period in which they received the drug 
(about 15% of their original weight) (Figure 5). Nevertheless, after the suppression of 
the treatment, the animals recovered their normal weight. For animals treated with 
DTX-NP-mPEG2 orally, their slimming was in all cases less than 5% of their original 510 
weight (Figure 5). Significant differences were observed in the body weight of the 
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animals treated with iv DTX compared with the control mice (non-treated animals) 
(p<0.05) and with DTX-NP-mPEG2 treated group (p<0.01, data not shown). 
Table 4 summarizes the most important signs of toxicity recorded throughout the study. 
For animals treated with either DTX or DTX-NP-mPEG2, one animal of each group died. 515 
More particularly, the animals treated iv with free docetaxel displayed a low mobility 
and signs of bristly hair and respiratory distress (Table 4).  These clinical signs were more 
severe just after each drug administration. For animals treated orally with DTX-NP-
mPEG2 any sign of disease stress and prejudice of their health status was observed 
(Table 4).  520 
On the other hand, on day 21 after the first administration, animals treated with DTX 
showed clinical signs of peripheral neuropathy such as impaired gait and hind limb splay 
(2/5); however, no neurotoxicity reactions appeared on the control group and the 
animals treated with oral nanoparticles. On the other hand, on day 35 after the first 
administration, serious dermatitis/necrosis (skin reactions) were noted on the tails of 525 
mice (2/5) treated iv with DTX (data not shown). 
After the oral administration of docetaxel-loaded in poly(anhydride)-mPEG2000 
conjugate nanoparticles or the iv docetaxel, the hematology parameters were analyzed. 
Figure 6 summarizes the changes in RBC, HCT, Hb and MCHC both in the medium (day 
14) and the late-term (day 35) of the test. As observed, on day 14, mice treated with iv 530 
docetaxel showed a marked decrease in RBC (65%), HCT (50%), Hb (65%) and MCHC 
(30%), compared with those of the basal levels (day 0). These data were correlated with 
mean values of RBC<8 x 106/μL, HTC<40%, Hb<14 g/dL and MCHC<35 g/dL, which were 
associated with anemia (Wolford et al., 1986). Although, no treatment-related changes 
were noted after the oral administration of DTX-NP-mPEG2.       535 
Figure 7 represents the changes in WBC and ANC. As can be seen in Figure 7A, on day 
21 and 35, the animals treated with iv DTX displayed a marked decrease in the WBC 
levels compared with nanoparticles group (70% vs. 40 % of the basal levels (day 0), 
respectively) and could be correlated with mean values of WBC<3.5 x 103/μL, which 
evidenced moderate leukopenia at these time points (Wolford et al., 1986; Olfert et al., 540 
1993). Besides, as observed in Figure 7B, docetaxel administered intravenously reduced 
significantly the ANC with mean values <1.0 x 103/μL, which implied that the mice of this 
group developed moderate neutropenia (Wolford et al., 1986). By contrast, the effect 
on mice after administration of DTX-NP-mPEG2 was less severe. 
Other hematologic markers including mean corpuscular haemoglobin (MCH) and mean 545 
corpuscular volume (MCV) had no statistically significant differences among the two 
groups (data not shown). Regarding WBC differential count, no obvious differences 
between both treatments were found. 
Finally, to assess the systemic toxicity of formulations, a number of biochemical 
parameters in serum such as AST, ALT, urea and creatinine, were also measured. Table 550 
5 shows the biochemical parameters registered. The values were always within the 
reference ranges (Olfert et al., 1993). However, the AST and ALT values on day 7 showed 
significant differences between DTX and DTX-NP-mPEG2 (p<0.05). 
 
4. Discussion 555 
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The synthesis of Gantrez® AN-poly(ethylene glycol) conjugates (PEG2 and mPEG2) was 
performed after dissolving the copolymer of methyl vinyl ether and maleic anhydride 
and the PEG in acetone, at a temperature of 50ºC for 3 hours, following by purification 
step with dichloromethane and a final drying step. The reaction between the carbonyl 
group of the Gantrez® AN and a hydroxyl group of the poly(ethylene glycol) was 560 
confirmed by IR analysis (Figure 1) and 1H-RMN (Supplementary material). The 
substitution degree was calculated to be 2.1 for PEG2 conjugate (about 21 μg of 
PEG2000 per mg of conjugate) and 7.1 for mPEG2 conjugate (71 μg of PEG2000 per mg 
of conjugate).  
Nanoparticles from both Gantrez® AN-PEG2000 and Gantrez® AN-mPEG2000 565 
conjugates were prepared by a simple desolvation method with an ethanol:water 
mixture (1:1 by vol.) in the presence of calcium chloride. The incorporation of calcium 
enabled us to increase the yield of the preparative process (data not shown). This would 
be directly related with the presence of ionic interactions between the divalent metal 
ion (calcium) and two neighbouring carboxylic groups in Gantrez® AN, which induces 570 
intrachain associations, promoting the cross-linking of the conjugate (Dong et al., 2011). 
The obtained poly(anhydride)-PEG2000 conjugate nanoparticles displayed a mean size 
higher than those in which mPEG2000 was used (around 420 nm vs. 340 nm). Regarding 
the encapsulation of docetaxel, the amount of docetaxel loaded in this nanoparticles 
was not dependent on the type of PEG employed for the conjugation and was calculated 575 
to be about 100 μg/mg nanoparticle, around 10-times the loading capacity of the 
unmodified poly(anhydride) (data not shown). 
For the in vitro release of docetaxel from DTX-NP-PEG2 and DTX-NP-mPEG2 
formulations, it is noteworthy that docetaxel was released at a considerably lower rate 
under acidic conditions (SGF). This fact can be explained by the low propensity of the 580 
poly(anhydride) polymer to undergo hydrolysis in an acid medium (Cai et al., 2003) 
preventing the swelling and degradation of the nanoparticles. However, when 
nanoparticles were incubated under neutral conditions (SIF) a complete release of the 
loaded drug was reached with small differences between conjugate nanoparticles.  
Concerning the pharmacokinetic study, a single dose of 30 mg docetaxel per kg bw was 585 
selected. When free docetaxel was administered intravenously to mice, docetaxel 
disposition was nonlinear (Figure 4). This profile is characteristic of the anticancer drug, 
which has been widely described previously (Ogura et al., 2016; van Tellingen et al., 
1999) and associated with the presence of Tween® 80 in the formula (Desai et al., 2008; 
Gan et al., 2010). Likely, the pharmacokinetic values obtained were found to be in line 590 
with those previously reported (van Tellingen et al., 1999).  
On the other hand, the oral administration of docetaxel after its encapsulation into the 
different poly(anhydride)-PEG conjugate nanoparticles offered high and prolonged in 
time drug plasma levels for at least 3 days (Figure 4). The long persistence of docetaxel 
in plasma was confirmed by the increase of MRT and half-life (t1/2z) values as compared 595 
with the iv DTX (Table 3). Another important point to highlight would be that, for both 
types of nanoparticles, the plasma levels of docetaxel were always quantified within the 
therapeutic window of the anticancer drug (between 35 ng/mL and 2700 ng/mL) 
(Saremi et al., 2011, Gan et al., 2010). Moreover, the high volume of distribution (V) 
observed for nanoencapsulated docetaxel formulations (Table 3), evidenced an 600 
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effective arrival of the drug to the general circulation and an extensive distribution to 
tissues after absorption. Interestingly, the clearance of docetaxel when orally 
administered as nanoparticles was similar to that calculated for iv DTX. In this context, 
the relative oral bioavailability of nanoencapsulated docetaxel was calculated to be 
about 40% for DTX-NP-PEG2 and 56% for DTX-NP-mPEG2. These values are significantly 605 
higher than the reported oral bioavailability of docetaxel (formulated as free drug), 
which would be lower than 4% (Bardelmeijer et al., 2002; Hu et al., 2012). 
These findings would be related with the mucus-permeating properties that may be 
obtained by the presence of PEG on the surface of nanoparticles. It is possible to 
hypothesize that during the formation of nanoparticles the hydrophilic moieties of 610 
conjugates would be oriented outside towards aqueous medium forming a hydrophilic 
corona-type surface, which would confer a “slippery” effect in the resulting 
nanoparticles. As a consequence, the capability of nanoparticles to move and cross the 
protective mucus layer would be improved, facilitating their arrival to the surface of the 
enterocytes (Zabaleta et al., 2013). In this localization, the effect of the clearance 615 
mechanism (i.e., peristalsis) would be reduced, extending the residence time of 
nanoparticles in close contact with the epithelium surface in which the cargo would be 
release in a sustained way. It is important to highlight that these “slippery” properties 
are directly related with the surface graft density of PEG on nanocarriers (Wang et al., 
2008), thus, high or dense PEG-packed surface greatly accelerated the transport of 620 
nanoparticles through the mucus, which would explain the higher oral bioavailability for 
DTX-NP-mPEG2 (high covalent grafting) compared with DTX-NP-PEG2. In parallel, the 
presence of PEG residues in this epithelial surface would facilitate its moderate 
inhibitory capacity of the intestinal efflux pump P-gp and cytochrome P450 (van 
Herwaarden et al., 2007; van Waterschoot et al., 2009), minimising the pre-systemic 625 
metabolism of docetaxel, and thus contributing to enhance its absorption. 
Finally, to determine the function of poly(anhydride)-PEG conjugate nanoparticles for 
reducing the toxicity of docetaxel clinical formulation, DTX and DTX-NP-mPEG2 
formulations were evaluated in healthy Balb/c mice. For the evaluation, three doses for 
DTX (30 mg/kg/injection), and nine doses for conjugate nanoparticles (20 mg/kg/dose) 630 
were administered to compare equitoxic doses. Thus, the accumulative dose for DTX-
NP-mPEG2 was the same that for DTX (90 mg/kg) and close to the mean optimal total 
dose of Taxotere® in mice (80 mg/kg) (Bissery et al., 1991; Aston et al., 2017). The mice 
in the DTX group suffered marked weight loss of about 15% during the treatment period, 
indicating severe toxicity, whereas the mice in the DTX-NP-mPEG2 suffered weight loss 635 
less than 5% (Figure 5). Furthermore, the animals treated intravenously with DTX 
displayed important signs of disease stress after each administration and clinical sings 
of hypersensitivity and peripheral neurotoxicity following the treatment period (Table 
4). These clinical manifestations would be directed related with the presence of the non-
ionic surfactant polysorbate 80 (Tween® 80) as a solvent in Taxotere® formulation. The 640 
oxidation products and oleic acid present in Tween® 80 may be the main cause of 
hypersensitivity reactions including serious dermatitis/necrosis (Ten Tije et al., 2003; 
Lucente et al., 2000). Moreover, Tween® 80 is capable of producing vesicular 
degeneration, contributing to the multifactorial mechanism of taxane-induced 
peripheral neurotoxicity (Ten Tije et al., 2003). On the other hand, for free docetaxel, 645 
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severe haematological adverse effects include anemia, leukopenia and neutropenia 
were observed in mice (Figures 6 and 7). On the contrary, for animals treated with 
nanoencapsulated docetaxel, the adverse effects were markedly less severe (Figures 6 
and 7). The haematological adverse effects observed in animals treated with free 
docetaxel may be due to the myelosuppression effect, characterized by a pancytopenia 650 
in which the neutrophils are severely affected, observed when toxic levels of the 
anticancer drug are reached (Frederiks et al., 2015). In a similar way, the biochemical 
parameters (AST, ALT, urea and creatinine) reflected alterations in blood enzymes. 
Particularly, in the DTX group, a significant increase in ALT and AST activity was observed 
after the first iv administration, suggesting drug-associated hepatotoxicity (Li et al., 655 
2010) (Table 5). By contrast, non-relevant changes were measured in animals treated 
with DTX-NP-mPEG2 (Table 5). 
All of these results evidence the good tolerance for nanoencapsulated docetaxel orally 
administered, when compared with iv docetaxel. This observation may be directly 
related with the different profiles of the drug in plasma as well as to the absence of 660 
polysorbate 80 in the nanoparticle formulations. In fact, after iv docetaxel 
administration, polysorbate 80 adopts a micellar structure able to entrap docetaxel (Ten 
Tije et al.,2003). These micelles would act as the principal carriers of docetaxel in 
systemic circulation, decreasing the free drug fraction available for distribution to 
peripheral tissues (van Tellingen et al., 1999; Nassar et al., 2011). As a consequence, this 665 
accumulation of docetaxel in plasma would contribute to the common hematological 
side effects reported in clinical treatment (Cho et al., 2014; Gan et al., 2010).  
 
5. Conclusions 
This study demonstrated that poly(anhydride)-PEG conjugate nanoparticles were able 670 
to load docetaxel, presenting suitable characteristics for its oral administration. 
Pharmacokinetic studies revealed the high capability of these nanocarriers to enhance 
the oral bioavailability of docetaxel, particularly with nanoparticles made from mPEG2, 
offering plasma levels of the anticancer drugs within the therapeutic window for at least 
three days after administration. Furthermore, docetaxel-loaded nanoparticles orally 675 
administered displayed less severe signs of toxicity (i.e., hypersensitivity reactions, 
peripheral neurotoxicity, myelosuppression and hepatotoxicity) than free iv docetaxel, 
when equitoxic doses were compared.  
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Figure 1. IR spectra of Gantrez® AN and its conjugates with either PEG2000 (PEG2) or 
mPEG2000 (mPEG2). Synthesis experimental conditions: PEG2000/poly(anhydride) 
ratio 0.05:1; mPEG2000/poly(anhydride) ratio 0.2:1; incubation time 3 h, 50ºC. 
 
Figure 2. Field emission scanning electron microscopy (FESEM) images of docetaxel-
loaded nanoparticles: A) DTX-NP-PEG2 and B) DTX-NP-mPEG2. 
 
Figure 3. Docetaxel release profile from the PEG-conjugate nanoparticle formulations 
after incubation in simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) at 
37ºC. Data represented as mean ± S.D. (n=3). 
 
Figure 4. Docetaxel plasma concentration-time profile after the iv and oral 
administration of DTX (dose 30 mg/kg bw) and the oral administration of docetaxel 
loaded nanoparticles: DTX-NP-PEG2 and DTX-NP-mPEG2 (dose 30 mg/kg bw). Data are 
expressed as mean ± S.D., n=4 per time point. 
 
Figure 5. Evolution of the body weight (bw) of animals. Bw is expressed as a percentage 
of the starting weight of individual animals. Data represented as mean ± S.D., (n=4). 
*p<0.05 Mann-Whitney U-test iv DTX vs. control. 
 
Figure 6. Hematological changes measured in mice through toxicity study compared 
with the basal levels. A) Red blood corpuscles count (RBC); B) Hematocrit (HCT); C) 
Hemoglobin (Hb); D) Mean corpuscular hemoglobin concentration (MCHC). Data 
represented as mean ± S.D. (*) p<0.05 Mann Whitney U-test DTX day 0 (basal levels) vs. 
DTX day 14. (**) p<0.01 Mann Whitney U-test DTX basal levels (day 0) vs. DTX day 14. 
 
Figure 7. Hematological changes in white blood cells registered in mice through toxicity 
study. A) White blood corpuscles count (WBC); B) Absolut neutrophil counts (ANC). The 
dotted lines indicate the reported range of normal values (Wolford et al., 1986). Data 










































Table 1. Estimated degree of substitution (% DS) and amount of PEG attached for the 
different conjugates synthesised calculated by HPLC-ELSD. PA: poly(anhydride). Data are 
expressed as mean ± S.D. (n=4). 
 
 PEG-to-PA ratio DS (%) PEG attached (μg/mg conjugate) 
PEG2 0.05:1 2.2 ± 0.5* 22.1 ± 3.2* 
mPEG2 0.2:1 8.1 ± 0.9 80.5 ± 9.1 
*p<0.05 Mann Whitney U-test DTX-NP-PEG2 vs. DTX-NP-mPEG2. 
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Table 2. Physico-chemical characterization of nanoparticles based on the synthetised 
conjugates. Data are expressed as mean ± S.D. (n=4). NP-PEG2: control nanoparticles 
obtained from the Gantrez® AN-PEG2000 conjugate; NP-mPEG2: control nanoparticles 
obtained from the Gantrez® AN-mPEG2000 conjugate; DTX-NP-PEG2: docetaxel-loaded 
in nanoparticles obtained from the Gantrez® AN-PEG2000 conjugate; DTX-NP-mPEG2: 















loading      
(μg/mg NP) 
NP-PEG2 307±9 -36±2 70±1 - - 
DTX-NP-PEG2 415±4  -33±2 64±9 58±7 94±5 
NP-mPEG2 297±9 -40±2 68±2 - - 




Table 3. Pharmacokinetic parameters of docetaxel obtained after the iv and oral administration of the commercial docetaxel (DTX) and 
nanoparticles encapsulating docetaxel at a single dose of 30 mg/kg bw to female Balb/c mice.  
 
  Formulation Route 
AUC 

















DTX iv 145.4± 4.9 177.9±25.1 - 1.4± 0.1 1.5±0.1 0.46±0.01 0.2±0.1 0.5±0.1 100 
DTX p.o N.D N.D N.D N.D N.D N.D N.D N.D N.D 
DTX-NP-PEG2 p.o 58.1±7.8*† 1.7±0.2 2 58.7±7.8* 35.8±9.2* 0.03±0.02* 0.2±0.1 11.2±4.1* 40.1 
DTX-NP-mPEG2 p.o 80.6±9.8* 1.7±0.1 1.5 61.1±7.6* 43.1±4.3* 0.02±0.01* 0.2±0.1 14.1±2.3* 55.5 
AUC: Area under the concentration-time curve from time 0 to t h; Cmax: Peak plasma concentration; Tmax: Time to reach peak plasma 
concentration; t1/2 z: Half-life of the terminal phase; Ke: elimination rate constant; Cl: Clearance; V: Volume of distribution; MRT: Mean residence 
time; Fr: relative oral bioavailability. (*) p<0.05 Mann-Whitney U-test DTX-NP-PEG2 vs. DTX iv, DTX-NP-mPEG2 vs. DTX iv.; (†) p<0.05 Mann 








Table 4. Mortality rate and signs scored after iv administration of docetaxel (dose 30 
mg/kg bw; weekly) and oral administration of DTX-NP-mPEG2 (dose 20 mg/kg bw; three 
times per week) during three consecutive weeks (Control and DTX, n=5; DTX-NP-mPEG2, 
n=8). 
 5 





Control - - - - - 0/5 
DTX +++ ++ +++ - +++ 1/5 
DTX-NP-
mPEG2 - - - - - 1/8 







Table 5. Biochemical parameters detected on day 0 (basal levels) and on day 7 and 35 
after the first dose of iv DTX or oral docetaxel-loaded in nanoparticles obtained from the 
Gantrez® AN-mPEG2000 conjugate. AST: Aspartate transaminase; ALT: Alanine 
transaminase. 
 5 
 Day 0 Day 7 Day 35 





AST (U/L) 94.5±23.4 96.3±26.4 154.5±55.6* 71.7±5.1 94.8±24.9 75.3±23.7 
ALT (U/L) 46.1±11.1 36.1±2.8 62.5±2.6* 33.7±4.7 45.5±11.5 43.8±22.1 
Urea 
(mg/dL) 39.3±2.6 34.1±5.3 33.1±8.5 40.3±7.5 31.8±8.9 36.7±10.6 
Creatinine 
(mg/dL) 0.1±0 0.1±0 0.1±0 0.1±0 0.2±0.1 0.1±0 
*p<0.05 Mann-Whitney U-test iv DTX vs. DTX-NP-mPEG2 
 
